RXi Pharmaceuticals (RXII) Sees Large Volume Increase

RXi Pharmaceuticals Corp (NASDAQ:RXII) saw strong trading volume on Wednesday . 1,003,044 shares traded hands during mid-day trading, an increase of 527% from the previous session’s volume of 159,988 shares.The stock last traded at $4.55 and had previously closed at $3.20.

The firm has a market capitalization of $10.78, a P/E ratio of -0.42 and a beta of 1.75.

COPYRIGHT VIOLATION NOTICE: This piece of content was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://ledgergazette.com/2018/03/14/rxi-pharmaceuticals-rxii-sees-large-volume-increase.html.

RXi Pharmaceuticals Company Profile

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.

Receive News & Ratings for RXi Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply